TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/24/2025
-
Ticker Report
4/15/2025
-
Ticker Report
4/10/2025
-
MarketBeat
4/9/2025
-
MarketBeat
4/8/2025
-
Benzinga
4/2/2025
-
MarketBeat
3/31/2025
-
GuruFocus
3/31/2025
-
Globe Newswire
3/27/2025
-
GuruFocus
3/27/2025
-
TipRanks Financial Blog
3/27/2025
-
The Fly
3/27/2025
-
Globe Newswire
3/15/2025
-
MarketBeat
3/15/2025
-
MarketBeat
3/14/2025
-
The Fly
3/10/2025
-
MarketBeat
3/8/2025
-
MarketBeat
3/7/2025
-
Ticker Report
3/7/2025
-
MarketBeat
3/7/2025
-
The Fly
3/7/2025
-
TipRanks Financial Blog
3/6/2025
-
MarketBeat
3/6/2025
-
MarketBeat
3/6/2025
-
MarketBeat
3/6/2025
-
Benzinga
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, March 5, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 399 9500
Address
830 Winter Street
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
Business Description
Sector
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The...
more